TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06712199
Drug: oxalidine
Normalized name: 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opioid anesthesia group (OBA group) Anesthesia was induced with propofol 2.5mg·kg-1, rocuronium 0.6mg·kg-1 and sufentanil 0.3μg·kg-1. When BIS value reached 40-60, tracheal intubation was performed through visual laryngeal mask airway. Anesthesia was maintained with propofol 4-12 mg·kg-1·h-1 and remifentanil 0.2-0.5 μg·kg-1·min-1. Sufentanil 10μg was bridaged 30min before the end of surgery. The PCA dosing regimen was sufentanil 2 µg/kg+ dexmedetomidine 2 µg/kg+ ondansetron 24mg.~Reduced-opioid anesthesia group (OFA group)~Anesthesia was induced with propofol 2.5mg·kg-1, rocuronium 0.6mg·kg-1 and esketamine 0.3mg·kg-1. When BIS value reached 40-60, tracheal intubation was performed through visual laryngeal mask airway. Propofol 4-12 mg·kg-1·h-1 and esketamine 0.3-0.5 mg·kg-1·h-1 were pumped to maintain anesthesia during operation. Oxalidine 1.5mg was given in two divided doses of 0.75mg each time with an interval of 10min 30min before the end of surgery. The PCA regimen was as follows:
Study: NCT05785429
Drug: Colchicine 0.5 MG
Normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant in the intervention group receive one tablet of 0.5mg colchicine per day for 12 weeks.
Study: NCT04312789
Drug: Avatrombopag
Normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06380348
Drug: JMT101 Injection
Normalized name: Jmt101 (fully human monoclonal igg1 antibody targeting epidermal growth factor receptor (egfr))
DrugBank: Becotatug (DB19069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 days
Study: NCT05231460
Drug: non-narcotic regimen with TAP block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Non-narcotic Pain Regimen post-operatively:~* Toradol 15mg q6h~* Tylenol 1000mg q8h~* Gabapentin 100mg three times a day
Study: NCT05231460
Drug: non-narcotic regimen with no TAP block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will not receive TAP block and will be administered the following Non-narcotic Pain Regimen post-operatively:~* Toradol 15mg q6h~* Tylenol 1000mg q8h~* Gabapentin 100mg three times a day
Study: NCT06380348
Drug: Osimertinib tablet
Normalized name: Osimertinib Tablets
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib 160mg once po everyday
Study: NCT05299008
Drug: Bethanechol
Normalized name: Bethanechol
DrugBank: Bethanechol (DB01019)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infants whom will be treated with bethanechol for tracheobronchomalacia in level IV center Neonatal Intensive Care Unit.
Study: NCT06380348
Drug: Cisplatin injection
Normalized name: cisplatin Injection
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75mg/m\^2, IV infusion, on day-1 at every cycle of 21days, 4 cycles at most.
Study: NCT06380348
Drug: Pemetrexed injection
Normalized name: pemetrexed Injection
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500mg/m\^2, IV infusion, on day-1 at every cycle of 21 days.
Study: NCT05594407
Drug: dexmedetomidine-ketamine-lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the DKL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution
Study: NCT05213208
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using \> 200 mg of propofol sedation colonoscopy is performed. 90-120 minutes after colonoscopy subjects go home. Within 1 week patients will be asked about their condition and satisfaction for colonoscopy.
Study: NCT05144217
Drug: 2x 140 mg per day
Normalized name: deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 capsule per day of silimarit
Study: NCT04410913
Drug: Psilocybin plus Visual Healing Set and Setting
Normalized name: dimethicone
DrugBank: Psilocybin (DB11664)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychedelic session (psilocybin 25 mg) with a therapist who will guide and accompany participants before, during, and after the psychedelic session. In addition, participants will have the chance to view nature-themed videos before and after the psychedelic sessions. Four weeks later, a second psychedelic session (psilocybin 25 mg) with either Visual Healing or standard Set and Setting procedures (patient's choice).
Study: NCT04410913
Drug: Psilocybin plus Standard Set and Setting
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychedelic session (psilocybin 25 mg) with a therapist will guide and accompany participants before, during, and after the psychedelic session. Four weeks later, a second psychedelic session (psilocybin 25 mg) with either Visual Healing or standard Set and Setting procedures (patient's choice).
Study: NCT05088057
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg on Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles (Q3W), intravenous (IV) infusion.
Study: NCT05088057
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m² on Day 1 of Cycles 1-4 (Q3W) or Cycles 5-8 (Q3W) of the neoadjuvant phase of the study, IV infusion;
Study: NCT05988879
Drug: Peginterferon alfa-2b Injection
Normalized name: peginterferon alfa-2b Injection
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The pegylated interferon α-2b injection is administered subcutaneously at a dose of 180ug once a week.
Study: NCT06507657
Drug: empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intake of a 10mg empagliflozin oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study.
Study: NCT05479045
Drug: Toripalimab-tpzi
Normalized name: toripalimab-tpzi
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 milligrams (mg), intravenously, every 3 weeks starting with the second dose of NY-ESO-1 Peptide vaccine
Study: NCT05860881
Drug: Sirolimus Topical Cream
Normalized name: sirolimus Topical Product
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The intervention topical cream consists of sirolimus 1% in a vehicle. Patients randomised to the intervention will be required to apply the sirolimus topical cream to their face for 6 months
Study: NCT05971537
Drug: conventional IP antibiotics
Normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the control arm, appropriate IP antibiotics are to be continued. The dosage and duration of antibiotics will fully follow the recommendation from the latest International Society for Peritoneal Dialysis (ISPD) peritonitis guidelines
Study: NCT05802862
Drug: Insulin Degludec and Insulin Aspart
Normalized name: insulin degludec and insulin aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administered subcutaneously, once a day
Study: NCT06164834
Drug: Clopidogrel 75 mg
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75 mg tablet
Study: NCT06164834
Drug: Tegoprazan 25 mg
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 25 mg tablet
Study: NCT06164834
Drug: Esomeprazole 20mg
Normalized name: ESOMEPRAZOLE 20MG (BASE) CAP,EC
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 20 mg tablet
Study: NCT06182969
Drug: APG-2575
Normalized name: APGA
DrugBank: Aminopterin (DB08878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take orally once daily (QD) for 12 weeks.
Study: NCT05802992
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigational drug colchicine was used at a daily dose of 0.5-1 mg. In every cycle, lenalidomide was administered at 10-25 mg (days 1-21). Dexamethasone 40mg (≤75 years old) or 20mg (\>75 years old) per week.If the weekly dose of dexamethasone is 40mg, it should be taken in the first two days of the week, 20mg per day; If the weekly dose is 20mg or take the lower dose on the first day of each week.~If the patient needs to be treated with the investigational drug colchicine on the day of dexamethasone administration, he should take dexamethasone orally within 3 hours before the administration of colchicine.
Study: NCT06020781
Drug: bupivacaine and dexmedetomidine.
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% + 1 μg/kg dexmedetomidine.
Study: NCT06020781
Drug: bupivacaine only
Normalized name: Bupivacaine only product
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% without additives
Study: NCT06020781
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 30 ml bupivacaine 0.5% without additives as a control group.
Study: NCT05319353
Drug: Maribavir
Normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive maribavir.
Study: NCT06268964
Drug: Trimebutine
Normalized name: trimebutine
DrugBank: Trimebutine (DB09089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of trimebutine at pediatric dosage (15 mg/kg/day), divided into 2 daily doses, for 8 weeks.
Study: NCT05802992
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In every cycle, lenalidomide was administered at 10-25 mg (days 1-21). Dexamethasone 40mg (≤75 years old) or 20mg (\>75 years old) per week.If the weekly dose of dexamethasone is 40mg, it should be taken in the first two days of the week, 20mg per day; If the weekly dose is 20mg or take the lower dose on the first day of each week.
Study: NCT05287724
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1,500 mg twice daily for seven days
Study: NCT04563195
Drug: tibulizumab (LY3090106)
Normalized name: ibalizumab
DrugBank: Tibulizumab (DB14848)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: subcutaneous injections of 300mg every 2 weeks over a period of 12 weeks
Study: NCT04994522
Drug: Belzutifan
Normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three 40 mg tablets given as a single oral 120 mg dose.
Study: NCT05476783
Drug: TB006
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Clear to slightly opalescent, sterile solution for injection
Study: NCT05421013
Drug: STP705
Normalized name: STP705 (small interfering RNA (siRNA) therapeutic directed against transforming growth factor-beta 1 (TGF-beta 1) and cyclo-oxygenase-2 (COX-2))
DrugBank: Cotsiranib (DB18404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: STP705 targets TGFB-1 and COX-2 mRNA respectively.
Study: NCT06128369
Drug: Dexamethasone Ophthalmic Suspension
Normalized name: Dexamethasone Ophthalmic Suspension
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ophthalmic Suspension,1.5% \[15 mg/mL\] Subjects will dose 1 drop of OCS-01 in the study eye once daily for 14 days, beginning 1-day post-surgery in the operated eye (administration of first dose will be performed in the clinic on Day 1).
Study: NCT06674525
Drug: 626
Normalized name: R1626
DrugBank: R1626 (DB05060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous injection
Study: NCT05784870
Drug: Ferrous succinate
Normalized name: Ferrous succinate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment with ferrous succinate 1 week before chemotherapy, usage: 200mgqd, for 28 consecutive days
Study: NCT04617600
Drug: MTA
Normalized name: HMTA
DrugBank: 5'-S-methyl-5'-thioadenosine (DB02282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survival rate using MTA in cariously exposed vital primary molars
Study: NCT04617600
Drug: TheraCal PT
Normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survival rate using TheraCal PT in cariously exposed vital primary molars
Study: NCT05612594
Drug: Bexagliflozin 20 mg
Normalized name: bexagliflozin 20 MG
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg once daily
Study: NCT04882358
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment with a standard dose of SGLT-2 inhibitor
Study: NCT06725368
Drug: PCC
Normalized name: PCC
DrugBank: Factor IX Complex (Human) (DB11330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCC protocol (Paclitaxel - Carboplatin - Cetuximab) by intravenous injection for 16 cycles. 1 cycle lasts 1 week. The Carboplatin + Paclitaxel administration schedule 3 weeks out of 4, with weekly Cetuximab is authorized.~After 16 cycles: maintenance with Cetuximab 500 mg/m2 every 14 days until unacceptable toxicity or progression or death.
Study: NCT06001372
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine, 0.5-1.2mg/kg, administered intramuscularly~* Doses can range 0.5-1.2 mg/kg. Starting dose for all participants will be 0.5mg/kg.~* Dose can be titrated up to maximum of 1.2 mg/kg or titrated down to 0.5 mg/kg based on response and clinical judgement.~* Dose will be administered by injecting into large muscle mass (eg, deltoid, gluteal muscle, thigh)
Study: NCT06537674
Drug: Trastuzumab intravenous drip/Trastuzumab Subcutaneous Injection
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Group A is Trastuzumab intravenous drip,Group B is Trastuzumab Subcutaneous Injection
Study: NCT05396144
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide will be administered by face or nasal mask to be inhaled by the patient
Study: NCT05630677
Drug: Rabeprazole, Delayed-release tablet
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive oral doses of rabeprazole twice daily 3 days prior to AZD5055 single dose and 4 days after the AZD5055 single dose including the day that AZD5055 is dosed under fasted conditions \[Study Day 10 to 18\].
Study: NCT05630677
Drug: Rabeprazole, Delayed-release tablet
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive oral doses of rabeprazole twice daily prior to AZD5055 single dose under fed conditions (low-fat standard breakfast) and then continued for 2 days.
Study: NCT05457400
Drug: ENSO 16
Normalized name: Ensovibep
DrugBank: Ensovibep (DB19078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g ENSO 16 dissolved in Water
Study: NCT05767359
Drug: Ciltacabtagene Autoleucel
Normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically modified autologous T-cell immunotherapy, via intravenous infusion per protocol.
Study: NCT05767359
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lymphodepleting conditioning regimen, synthetic purine nucleoside, via intravenous infusion per standard care.
Study: NCT04901104
Drug: Thymosin Alpha1
Normalized name: Thymosin alpha1 (human)
DrugBank: Thymalfasin (DB04900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug interventions have been done in previous clinical studies
Study: NCT05652530
Drug: Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This product is allogeneic NK cells which are cryopreserved after in vitro CAR genetic modification and scale-up manufacturing. Subjects are enrolled and treated with lymphocyte clearance chemotherapy (including pre-clearance evaluation), pre-infusion evaluation and BCMA CAR-NK cells infusion.
Study: NCT04713956
Drug: Granulocyte Colony-Stimulating Factor(G-CSF)
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
Study: NCT04713956
Drug: Decitabine (DAC)
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine was administered at 20mg/m2/day on days -14 to -10.
Study: NCT04713956
Drug: Busulfan (BU)
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
Study: NCT04713956
Drug: Fludarabine (FLU)
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
Study: NCT06082856
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction of general anesthesia by administration of dexmedetomidine 0.5µg/Kg (maximum dose 50 µg) in titration by bolus of 10µg intravenously over 5 minutes
Study: NCT05113537
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given Orally
Study: NCT05113537
Drug: Lutetium Lu 177-PSMA-617
Normalized name: Lutetium dotatate Lu-177
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06273397
Drug: Acetazolamide 250 MG
Normalized name: acetazolamide 250 MG
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide 250mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
Study: NCT06273397
Drug: Metolazone 2.5 MG
Normalized name: metolazone 2.5 MG
DrugBank: Metolazone (DB00524)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metolazone 2.5mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
Study: NCT05987397
Drug: idebenone 30 mg for 14 days
Normalized name: idebenone 30 MG
DrugBank: Idebenone (DB09081)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).
Study: NCT05987397
Drug: idebenone 30 mg for 3 months
Normalized name: idebenone 30 MG
DrugBank: Idebenone (DB09081)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.
Study: NCT06273397
Drug: Furosemide Injection
Normalized name: furosemide Injection
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous furosemide in a double daily dose. The dosage is determined by a predefined table based on the admission renal function and the outpatient dose prior to admission. In general terms, for patients with an estimated glomerular filtration rate above 60 ml/min/1.73m² or those experiencing heart failure debut, the dose will be 1x the outpatient dose. For those with a glomerular filtration rate below 60 ml/min/1.73m², the dose will be 2x the outpatient dose. The dosing protocol for this arm also serves as guidance for furosemide in the intervention arms.
Study: NCT06339619
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/kg ivgtt D1 Q3W
Study: NCT06339619
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg PO QD
Study: NCT06339619
Drug: Tegafur
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: dosing based on body surface area：BSA\<1.25m2,40mg; BSA=1.25～1.5m2,50mg; BSA\>1.5m2, 60mg，PO QD D1-21 Q3W
Study: NCT04522596
Drug: Umeclidinium/vilanterol
Normalized name: UMECLIDINIUM/VILANTEROL
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Umeclidinium/vilanterol 55/22 μg inhaled once a day
Study: NCT05671913
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment arm
Study: NCT04921007
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following negative aspiration, a precalculated dose (0.5 ml/kg) of 0.25% bupivacaine will be injected.
Study: NCT01728051
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05398510
Drug: SHR-2010 injection
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment for intravenously: 6 subjects for SR-2010 injection. Treatment for subcutaneously: 8 subjects for SR-2010 injection.
Study: NCT05946798
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each